Maia Hugo, Albernaz Marco Aurélio, Baracat Edmund Chada, Barbosa Ione Cristina, Bossemeyer Ronald, Bueno Alberto Hernández, Campos Oscar González, Carranza-Lira Sebastián, Casas Pedro Figueroa, Castro Alvaro Monterrosa, de Lima Geraldo Rodrigues, de Melo Nilson R, Fernandes César Eduardo, González Javier Santos, Larrañaga Francisco Espinosa, Siseles Néstor, Uribe Alfonso Murillo, Vilchez Rafael Molina
Department of Gynecology, Obstetrics and Human Reproduction, School of Medicine, Federal University of Bahia, Salvador, Behia.
Maturitas. 2006 Aug 20;55(1):5-13. doi: 10.1016/j.maturitas.2006.03.009. Epub 2006 May 3.
Data from placebo-controlled, randomized clinical trials conducted during the past few years resulted in critical re-evaluation of the overall health benefits of hormone therapy (HT) in women during the menopausal transition and thereafter. These data stimulated vigorous debate among experts and produced several position papers by North American and European authorities providing guidance on the use of HT. It is well known that cultural, geographic and ethnic differences influence the acceptance and risk perception of HT. Therefore, it was considered essential to present a position specifically relevant to Latin American countries.
A Latin American Expert Panel, convening in Salvador, Bahia, Brazil, obtained consensus on recommendations for HT that incorporated the findings of the most recently published reports. The panelists' opinions were surveyed by means of the Likert scale along five categories ranging from complete agreement to complete disagreement.
The Panel presented 13 recommendations and considered three additional issues relevant to HT use. There was consensus that HT during the perimenopause and thereafter is warranted in Latin American women in particular for the management of vasomotor symptoms. HT may also be an option for osteoporosis prevention in women at significant risk, after evaluation of risks/benefits and after consideration of alternative therapies. HT should be individualized and prescribed at the lowest effective dose.
The Panel concluded that HT remains a safe and effective treatment option for peri- and postmenopausal Latin American women.
过去几年进行的安慰剂对照随机临床试验的数据促使人们对激素疗法（HT）在绝经过渡期间及之后对女性整体健康益处进行了批判性的重新评估。这些数据引发了专家之间的激烈辩论，并促使北美和欧洲权威机构发表了几篇立场文件，为HT的使用提供指导。众所周知，文化、地理和种族差异会影响对HT的接受程度和风险认知。因此，认为有必要提出一份与拉丁美洲国家具体相关的立场文件。
一个拉丁美洲专家小组在巴西巴伊亚州萨尔瓦多召开会议，就纳入最新发表报告结果的HT建议达成共识。通过李克特量表对小组成员在从完全同意到完全不同意的五个类别上的意见进行了调查。
该小组提出了13项建议，并考虑了与HT使用相关的另外三个问题。达成的共识是，拉丁美洲女性在围绝经期及之后使用HT尤其适用于管理血管舒缩症状。在评估风险/益处并考虑替代疗法后，HT也可能是高危女性预防骨质疏松症的一种选择。HT应个体化并以最低有效剂量开具。
该小组得出结论，HT仍然是拉丁美洲绝经前后女性安全有效的治疗选择。
